Skip to main content
BLISSGVS · Health Care · 2026-08-21

Bliss GVS Pharma Ltd

7.8★★ GoodStrong +6.1Stage 2 · wk 37In scan: Prop Scan · Pullback HunterMARKET: BULL RISING · 2026-08-21
₹579.1
-0.18% today
₹6,154 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
33.1
Forward —
Earnings Growth (YoY)
-5.7%
Revenue +3.7%
Dividend Yield
0.26%
P/B 3.7
vs 52W High
-0.2%
₹127.6 lo₹580.2 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 37
1w13w26w
Week 37 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
100.0%
200 DMA: ₹289.5 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.34x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 trending up · +4.4% vs MA50 +11.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #1 of 84 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #1 of 58 Stage 2 stocks in this industry. Top stock in industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 17w
S3 16w
S2 38w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 3w → S3 1w → S2 17w → S3 4w → S2 13w → S3 16w → S4 8w → S1 5w → S2 10w → S3 1w → S2 11w → S3 6w → S4 9w → S1 6w → S2 11w → S3 9w → S2 38w current
Total tracked: 167 weeks across 17 stage runs.
1M
+25.4%
3M
+92.8%
6M
+161.5%
YTD
+254.7%
1Y
+240.0%
Scan Membership
Prop Scan
Latest: 2026-08-21
Pullback Hunter
Latest: 2026-08-10
60 appearances in last 60 days. First seen: 2026-06-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 37 · Vol x
2026-08-20S2
Wk 37 · Vol x
2026-08-19S2
Wk 37 · Vol x
2026-08-18S2
Wk 36 · Vol x
2026-08-17S2
Wk 36 · Vol x
2026-08-14S2
Wk 36 · Vol x
2026-08-13S2
Wk 36 · Vol x
2026-08-12S2
Wk 36 · Vol x
2026-08-11S2
Wk 35 · Vol x
2026-08-10S2
Wk 35 · Vol x
2026-08-07S2
Wk 35 · Vol x
2026-08-06S2
Wk 35 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹494.8
200 DMA
₹289.5
52W High
₹580.2
52W Low
₹127.6
5D Low
₹520.5
Resistance levels (recent highs)
20d High
₹580.2
60d High
₹580.2
120d High
₹580.2
250d High
₹580.2
Next resistance
+0.2%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.